Cancer Science
Return to Library
|
Free Cancer Science Articles |
|
|
|
|
Researchers from University of Tsukuba describe findings in cancer vaccines risk factors
2009 JUL 13 - (NewsRx.com) -- Current study results from the report, 'Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer,' have been published. "To obtain baseline data for human papillomavirus (HPV) screening and vaccination in Japan, we analyzed HPV DNA data from 2282 Japanese women (1517 normal cytology, 318 cervical intraepithelial neoplasia [CIN] grade 1, 307 CIN2-3, and 140 invasive cervical cancer [ICC]) that visited the University of Tsukuba Hospital or Ibaraki Seinan Medical Center Hospital for screening or treatment of cervical diseases between 1999 and 2007. An L1-based PCR method was used for individual HPV genotyping," scientists writing in the journal Cancer Science report. "The most common HPV types in ICC were, in order of decreasing prevalence, HPV16 (40.5%), HPV18 (24.4%), HPV52 (8.4%), HPV58 (3.1%), and HPV33 (3.1%). Based on the comparison of HPV type distributions between normal cytology and CIN2-3 and ICC, estimated risk of disease progression varied considerably by genotype: HPV16, HPV18, HPV31, HPV33, HPV35, HPV52, and HPV58 (prevalence ratio, 1.92; 95% confidence interval 1.58-2.34); other oncogenic types (0.31, 95% confidence interval 0.19-0.50); and non-oncogenic types (0.09, 95% confidence interval 0.03-0.43). HPV16 and/or HPV18, including coinfections with other types, contributed to 67.1% of ICC and 36.2% of CIN2-3 among Japanese women. More importantly, the overall prevalence of HPV16 and/or HPV18 varied greatly according to the women's age: highest in women aged 20-29 years (ICC, 90.0%; CIN2-3, 53.9%), decreasing with age thereafter, and lowest in women aged 60 years or older (ICC, 56.3%; CIN2-3, 25.0%)," wrote M. Onuki and colleagues, University of Tsukuba. The researchers concluded: "Type-specific HPV testing may help identify Japanese women at high risk of progression to CIN2-3 and cancer. In Japan, current HPV vaccines are estimated to provide approximately 70% protection against ICC and may be more useful in reducing the incidence of cervical cancer and precancer in young women of reproductive age." Onuki and colleagues published their study in Cancer Science (Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Science, 2009;100(7):1312-6). Additional information can be obtained by contacting M. Onuki, University of Tsukuba, Dept. of Obstetrics and Gynecology, Graduate School of Comprehensive Human Science, Tsukuba, Japan. The publisher of the journal Cancer Science can be contacted at: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA. Keywords: Japan, Tsukuba, Cancer Vaccines Risk Factors, Cancer Science, Cancer Vaccines, Cervical Cancer, Cervical Carcinoma, Cervical Disease, Cervical Intraepithelial Neoplasia, Cytology, DNA, Genotyping, HPV, Human Papillomavirus, Immunization, Oncology, Papillomavirus Infections, Vaccination, Women's Health. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
